SIETES :: 93212 citas

Resultados de la búsqueda por ANGIOEDEMA REFINAR BÚSQUEDA

1.

Tena B. UK recomienda que las personas alérgicas no se vacunen al registrar dos casos de reacciones. El Confidencial 2020:4. [Ref.ID 103810]

2.

Schuster BC, Brhlikova P, Heath J, McGettigan P. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011–2018. PLOS Medicine 2019;16:10 de septiembre. [Ref.ID 103247]

3.

Montané E, Arellano AL, Sanz Y, Roca J, Farré M. Drug-related deaths in hospital inpatients: a retrospective cohort study. Br J Clin Pharmacol 2017;84:1. [Ref.ID 102184]

4.

Anónimo. Sacubitril/valsartan (Entresto) for heart failure. Med Lett Drugs Ther 2015;57:107-9. [Ref.ID 99650]

5.

Kelley KK. New heart failure drug combo approved. Journal Watch 2015:1. [Ref.ID 99246]

6.

Bas M, Greve J, Stelter K, Havel M, Strassen U, Rotter N, Veit J, Schossow B, Hapfelmeier A, Kehl V, Kojda G, Hoffmann TK. A randomized trial of icatibant in ACE-inhibitor-induced angioedema. N Engl J Med 2015;372:418-25. [Ref.ID 98747]

7.

Jessup M, Komajda FM, McMurray JJV, Packer M. Perspective roundtable: PARADIGM-HF - The experts' discussion. N Engl J Med 2014;371:e15. [Ref.ID 98475]

8.

McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, for the PARADIGM-HF Investigators and Committees. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004. [Ref.ID 98005]

9.

Anónimo. Over-the-counter topical acne products: drug safety communication - Rare but serious hypersensitivity reactions. U.S. Food and Drug Administration 2014:25 de junio. [Ref.ID 97713]

10.

Anónimo. Pour mieux soigner: des médicaments à écarter. Prescrire 2013;33:138-42. [Ref.ID 94882]

11.

Katz MH. Risks and benefits of medications in real-worl practice: Comment on "Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system". Arch Intern Med 2012;172:1590. [Ref.ID 94055]

12.

Toh S, Reichman ME, Houstoun M, Southworth MR, Ding X, Hernandez AF, Levenson M, Li L, McCloskey C, Shoaibi A, Wu E, Zomberg G, Hennessy S. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch Intern Med 2012;172:1582-9. [Ref.ID 94053]

13.

Anónimo. Vildagliptin – a new oral antidiabetic agent. Signal 2011:13-4. [Ref.ID 91692]

14.

Anónimo. Conestt alfa. Juste un autre mode de production. Prescrire 2011;31:734. [Ref.ID 91599]

15.

Scheirey CD, Scholz FJ, Shortsleeve MJ, Katz DS. Angiotensin-converting enzyme inhibitor-induced small-bowel angioedema: clinical and imaging findings in 20 patients. AJR Am J Roentgenol 2011;197:393-8. [Ref.ID 91002]

16.

Anónimo. Prasugrel (Efient?): rare but serious hypersensitivity reactions. Drug Safety Update 2011;4:A1. [Ref.ID 90622]

17.

Thong BYH, Tan TC. Epidemiology and risk factors for drug allergy. Br J Clin Pharmacol 2011;71:684-700. [Ref.ID 90601]

18.

Arden-Jones MR, Friedmann PS. Skin manifestations of drug allergy. Br J Clin Pharmacol 2011;71:672-83. [Ref.ID 90600]

19.

Chaponda M, Pirmohamed M. Hypersensitivity reactions to HIV therapy. Br J Clin Pharmacol 2011;71:659-71. [Ref.ID 90599]

20.

Nel L, Eren E. Peri-operative anaphylaxis. Br J Clin Pharmacol 2011;71:647-58. [Ref.ID 90598]